drugset / Trial / NCT00037219

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219

Phase 2 Completed 120 enrolled Pfizer Vicuron Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.

Timeline

Start
2001-08
Primary completion
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Anidulafungin Other / unclassified Intravenous

Indications